Two cholesterol drugs for heart disease prevention
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a history of heart disease, stroke, or imaging evidence of clogged arteries (from prior angiography, CT scan, or ultrasound)
- You cannot tolerate or have a contraindication to statin therapy (the standard first-line cholesterol drug)
- Your fasting LDL cholesterol is between 2.5 and 5.0 mmol/L at screening
- You have been on stable cholesterol-lowering background therapy (such as ezetimibe) for at least 4 weeks before joining
- You have not previously taken any PCSK9 inhibitor medication (alirocumab, evolocumab, or inclisiran)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two cholesterol-lowering medicines, evolocumab and alirocumab, work in people with high cholesterol or heart disease. It reviews medical records from patients at a specific hospital to see how these medicines affect cholesterol levels.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
This study tests an extra medication (inclisiran) added to your usual cholesterol-lowering treatment, compared to usual treatment alone, to see if it further lowers 'bad' cholesterol after a recent heart attack.
This study tests whether coordinating care between your regular doctor and heart specialists helps manage chronic coronary disease. It focuses on people with high cholesterol despite taking strong statin medication.
This trial tests a new version of inclisiran, a cholesterol-lowering medicine, to see if it is safe and works well. The study compares it to the current version. You may qualify if you have moderately high cholesterol but have never taken cholesterol medications.
Hear when a new Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.